549 related articles for article (PubMed ID: 21296818)
1. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity.
Zhang X; Ren X; Li G; Jiao C; Zhang L; Zhao S; Wang J; Han ZC; Li X
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3143-52. PubMed ID: 21296818
[TBL] [Abstract][Full Text] [Related]
2. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
3. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
5. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
[TBL] [Abstract][Full Text] [Related]
6. Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis.
Suzuki J; Sakai J; Okada AA; Takada E; Usui M; Mizuguchi J
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):314-21. PubMed ID: 11981647
[TBL] [Abstract][Full Text] [Related]
7. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Kwak HJ; Yang YS; Pae HO; Kim YM; Chung HT
Mol Cells; 2001 Oct; 12(2):178-84. PubMed ID: 11710518
[TBL] [Abstract][Full Text] [Related]
8. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12.
Yokoi H; Kato K; Kezuka T; Sakai J; Usui M; Yagita H; Okumura K
Eur J Immunol; 1997 Mar; 27(3):641-6. PubMed ID: 9079803
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effects of mesenchymal stem cells in a rat corneal allograft rejection model.
Jia Z; Jiao C; Zhao S; Li X; Ren X; Zhang L; Han ZC; Zhang X
Exp Eye Res; 2012 Sep; 102():44-9. PubMed ID: 22800963
[TBL] [Abstract][Full Text] [Related]
10. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye.
Wildner G; Thurau SR
Eur J Immunol; 1995 May; 25(5):1292-7. PubMed ID: 7774632
[TBL] [Abstract][Full Text] [Related]
11. Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice.
Usui Y; Takeuchi M; Hattori T; Okunuki Y; Nagasawa K; Kezuka T; Okumura K; Yagita H; Akiba H; Goto H
Arch Ophthalmol; 2009 Apr; 127(4):514-9. PubMed ID: 19365033
[TBL] [Abstract][Full Text] [Related]
12. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
13. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030
[TBL] [Abstract][Full Text] [Related]
15. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens.
Egwuagu CE; Mahdi RM; Nussenblatt RB; Gery I; Caspi RR
J Immunol; 1993 Aug; 151(3):1627-36. PubMed ID: 8393049
[TBL] [Abstract][Full Text] [Related]
16. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor.
Zhang L; Ma J; Takeuchi M; Usui Y; Hattori T; Okunuki Y; Yamakawa N; Kezuka T; Kuroda M; Goto H
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2109-17. PubMed ID: 20007828
[TBL] [Abstract][Full Text] [Related]
17. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
[TBL] [Abstract][Full Text] [Related]
18. Everolimus improves experimental autoimmune uveoretinitis.
Hennig M; Bauer D; Wasmuth S; Busch M; Walscheid K; Thanos S; Heiligenhaus A
Exp Eye Res; 2012 Dec; 105():43-52. PubMed ID: 23059401
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of experimental autoimmune uveoretinitis with anti-macrophage migration inhibitory factor antibodies.
Kitaichi N; Matsuda A; Kotake S; Namba K; Tagawa Y; Sasamoto Y; Ogasawara K; Iwabuchi K; Onoé K; Matsuda H; Nishihira J
Curr Eye Res; 2000 Feb; 20(2):109-14. PubMed ID: 10617911
[TBL] [Abstract][Full Text] [Related]
20. Effects of systemic and intravitreal TNF-α inhibition in experimental autoimmune uveoretinitis.
Busch M; Bauer D; Hennig M; Wasmuth S; Thanos S; Heiligenhaus A
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):39-46. PubMed ID: 23211816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
